The purpose of this study was to compare the efficacy and safety of brigatinib and alectinib for ALK-p, ALK-inhibitor-naïve, advanced NSCLC, with and without CNS metastasis, by Bayesian network meta-analysis. Here, ALK is linked to non-small cell lung carcinoma.